Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial

被引：159
|
作者：
Reck, Martin [1 ]
Schenker, Michael [2 ]
Lee, Ki Hyeong [3 ]
Provencio, Mariano [4 ]
Nishio, Makoto [5 ]
Lesniewski-Kmak, Krzysztof [6 ]
Sangha, Randeep [7 ]
Ahmed, Samreen [8 ]
Raimbourg, Judith [9 ]
Feeney, Kynan [10 ,11 ]
Corre, Romain [12 ]
Franke, Fabio Andre [13 ]
Richardet, Eduardo [14 ]
Penrod, John R. [15 ]
Yuan, Yong [15 ]
Nathan, Faith E. [15 ]
Bhagavatheeswaran, Prabhu [15 ]
DeRosa, Michael [16 ]
Taylor, Fiona [16 ]
Lawrance, Rachael [17 ]
Brahmer, Julie [18 ]
机构：
[1] German Ctr Lung Res DZL, ARCN, LungenClin Grosshansdorf, Wohrendamm 80, D-22927 Grosshansdorf, Germany
[2] Cent Oncol Sf Nectarie, 23A Caracal St, Craiova 200347, Romania
[3] Chungbuk Natl Univ Hosp, 776,1 Sunhwan Ro, Cheongju 28644, Chungcheonbuk D, South Korea
[4] Univ Autonoma Madrid, Inst Invest Puerta Hierro, Hosp Puerta Hierro de Majadahonda, C Manuel de Falla 1, Madrid 28222, Majadahonda, Spain
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan
[6] Gdansk Med Univ, Oddzial Onkol Radioterapii Szpital, UI Powstania Styczniowego 1, PL-81519 Gdynia, Poland
[7] Cross Canc Inst, 11560 Univ Ave, Edmonton, AB T6G 1Z2, Canada
[8] Univ Hosp Leicester NHS Trust, Dept Infect, Leicester LE1 5WW, Leics, England
[9] Inst Cancerol Ouest, Ctr Rene Gauducheau, Blvd Jacques Monad, F-44805 Nantes, France
[10] Notre Dame Univ, 100 Murdoch Dr, Perth, WA 6150, Australia
[11] Edith Cowan Univ, 100 Murdoch Dr, Perth, WA 6150, Australia
[12] CHU Rennes, 2 Rue Henri le Guilloux, F-35033 Rennes, France
[13] Hosp Caridade Ijui, CACON, Av David Jose Martins, BR-98700000 Ijui, RS, Brazil
[14] IONC Univ Catolica Cordoba, Parana 560 2 Piso, RA-5000 Cordoba, Argentina
[15] Bristol Myers Squibb Co, 3401 Princeton Pike, Lawrenceville, NJ 08648 USA
[16] Adelphi Values, 290 Congress St 7th Floor, Boston, MA 02210 USA
[17] Adelphi Values, Grimshaw Ln, Bollington SK10 5JB, Cheshire, England
[18] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB1-G94, Baltimore, MD 21287 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2019年 / 116卷
关键词：
Antineoplastic agents; Carcinoma; Ipilimumab; Lung neoplasms; Nivolumab; Non-small-cell lung cancer; Platinum-doublet chemotherapy; Quality of life; Surveys and questionnaires; QUALITY-OF-LIFE; DOCETAXEL; SYMPTOMS; MULTICENTER;
D O I：
10.1016/j.ejca.2019.05.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: In the phase I I I CheckMate 227 study, first-line nivolumab + ipilimumab significantly prolonged progression-free survival (co-primary end-point) versus chemotherapy in patients with advanced nonesmall-cell lung cancer (NSCLC) and high tumour mutational burden (TMB; >= 10 mutations/megabase). Aim: To evaluate patient-reported outcomes (PROs) in this population. Methods: Disease-related symptoms and general health status were assessed using the validated PRO questionnaires Lung Cancer Symptom Scale (LCSS) and EQ-5D, respectively. LCSS average symptom burden index (ASBI) and three-item global index (3-IGI) and EQ-5D visual analogue scale (VAS) and utility index (UI) scores and changes from baseline were analysed descriptively. Longitudinal changes were assessed by mixed-effect model repeated measures (MMRMs) and time to first deterioration/improvement analyses. Results: In the high TMB population, PRO questionnaire completion rates were similar to 90% at baseline and >80% for most on-treatment assessments. During treatment, mean changes from baseline with nivolumab + ipilimumab showed early, clinically meaningful improvements in LCSS ASBI/3-IGI and EQ-5D VAS/UI; with chemotherapy, symptoms and health-related quality of life remained stable (LCSS ASBI/3-IGI, EQ-5D UI) or improved following induction (EQ-5D VAS). MMRM-assessed changes in symptom burden were improved with nivolumab + ipilimumab versus chemotherapy. Symptom deterioration by week 12 was lower with nivolumab + ipilimumab versus chemotherapy (22.3% versus 35.0%; absolute risk reduction: 12.7% [95% confidence interval 2.4-22.5]), irrespective of discontinuation. Time to first deterioration was delayed with nivolumab + ipilimumab versus chemotherapy across LCSS and EQ-5D summary measures. Conclusion: First-line nivolumab + ipilimumab demonstrated early, sustained improvements in PROs versus chemotherapy in patients with advanced NSCLC and high TMB. (C) 2019 The Authors. Published by Elsevier Ltd.
引用
收藏
页码：137 / 147
页数：11
相关论文
共 50 条
  • [41] Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
    Goldman, Jonathan W.
    Garassino, Marina Chiara
    Chen, Yuanbin
    Ozguroglu, Mustafa
    Dvorkin, Mikhail
    Trukhin, Dmytro
    Statsenko, Galina
    Hotta, Katsuyuki
    Ji, Jun Ho
    Hochmair, Maximilian J.
    Voitko, Oleksandr
    Havel, Libor
    Poltoratskiy, Artem
    Losonczy, Gyorgy
    Reinmuth, Niels
    Patel, Nikunj
    Laud, Peter J.
    Shire, Norah
    Jiang, Haiyi
    Paz-Ares, Luis
    LUNG CANCER, 2020, 149 : 46 - 52
  • [42] Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
    Reck, Martin
    Ciuleanu, Tudor-Eliade
    Schenker, Michael
    Bordenave, Stephanie
    Cobo, Manuel
    Juan-Vidal, Oscar
    Reinmuth, Niels
    Richardet, Eduardo
    Felip, Enriqueta
    Menezes, Juliana
    Cheng, Ying
    Mizutani, Hideaki
    Zurawski, Bogdan
    Alexandru, Aurelia
    Carbone, David P.
    Lu, Shun
    John, Thomas
    Aoyama, Takekazu
    Grootendorst, Diederik J.
    Hu, Nan
    Eccles, Laura J.
    Paz-Ares, Luis G.
    EUROPEAN JOURNAL OF CANCER, 2024, 211
  • [43] Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
    Chu, T.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Shi, C.
    Zhang, X.
    Qian, J.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S589 - S590
  • [44] Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial
    Ruike Gao
    Ying Zhang
    Wei Hou
    Jie Li
    Guanghui Zhu
    Xiaoxiao Zhang
    Bowen Xu
    Zhe Wu
    Heping Wang
    Trials, 22
  • [45] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
    Thatcher, Nick
    Hirsch, Fred R.
    Luft, Alexander V.
    Szczesna, Aleksandro
    Ciuleanu, Tudor E.
    Dediu, Mircea
    Ramlau, Rodryg
    Galiulin, Rinat K.
    Balint, Beatrix
    Losonczy, Gyoergy
    Kazarnowicz, Andrzej
    Park, Keunchil
    Schumann, Christian
    Reck, Martin
    Depenbrock, Henrik
    Nanda, Shivani
    Letunic, Anamarija Kruljac
    Kurek, Raffacl
    Paz-Ares, Luis
    Socinskf, Mark A.
    LANCET ONCOLOGY, 2015, 16 (07) : 763 - 774
  • [46] Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer
    Kawahara, Takuya
    Shimozuma, Kojiro
    Shiroiwa, Takeru
    Hagiwara, Yasuhiro
    Uemura, Yukari
    Watanabe, Takanori
    Taira, Naruto
    Fukuda, Takashi
    Ohashi, Yasuo
    Mukai, Hirofumi
    ONCOLOGY, 2018, 94 (02) : 107 - 115
  • [47] Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
    Shi, M.
    Gu, A.
    Tu, H.
    Huang, C.
    Wang, H.
    Yu, Z.
    Wang, X.
    Cao, L.
    Shu, Y.
    Yang, R.
    Li, X.
    Chang, J.
    Hu, Y.
    Shen, P.
    Guo, Z.
    Tao, M.
    Zhang, Y.
    Liu, X.
    Sun, Q.
    Zhang, X.
    Jiang, Z.
    Zhao, J.
    Chen, F.
    Yu, H.
    Zhang, W.
    Sun, J.
    Li, D.
    Zhou, J.
    Han, B.
    Wu, Y. L.
    ANNALS OF ONCOLOGY, 2021, 32 (01) : 85 - 96
  • [48] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
    Auclin, Edouard
    Benitez-Montanez, Jose
    Tagliamento, Marco
    Parisi, Francesca
    Gorria, Teresa
    Garcia-Campelo, Rosario
    Dempsey, Naomi
    Pinato, David J.
    Reyes, Roxana
    Albarran-Artahona, Victor
    Dall'Olio, Filippo
    Soldato, Davide
    Hendriks, Lizza
    Nana, Frank Aboubakar
    Tonneau, Marion
    Lopez-Castro, Rafael
    Nadal, Ernest
    Kazandjian, Suzanne
    Muanza, Thierry
    Blanc-Durand, Felix
    Fabre, Elizabeth
    Castro, Natalia
    Arasanz, Hugo
    Rochand, Adrien
    Besse, Benjamin
    Routy, Bertrand
    Mezquita, Laura
    LUNG CANCER, 2023, 178 : 116 - 122
  • [49] Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer
    Chang, Jianhua
    Wu, Yi-Long
    Lu, Shun
    Wang, Jie
    Mok, Tony
    Zhang, Li
    Feng, Jifeng
    Wu, Lin
    Tu, Hai-Yan
    Zhang, Yiping
    Luft, Alexander
    Zhou, Jian-ying
    Ma, Zhiyong
    Lu, You
    Hu, Chengping
    Shi, Yuankai
    Poddubskaya, Elena
    Soo, Ross A.
    Chia, Yee Hong
    Penrod, John R.
    Taylor, Fiona
    Lawrance, Rachael
    Blum, Steven, I
    Sun, Xiaowu
    Juarez-Garcia, Ariadna
    Moreno-Koehler, Alejandro
    Li, Ang
    Li, Amy
    Cheng, Ying
    LUNG CANCER, 2022, 165 : 71 - 81
  • [50] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
    Zhou, C.
    Wu, Y. L.
    Chen, G.
    Feng, J.
    Liu, X. -Q.
    Wang, C.
    Zhang, S.
    Wang, J.
    Zhou, S.
    Ren, S.
    Lu, S.
    Zhang, L.
    Hu, C.
    Hu, C.
    Luo, Y.
    Chen, L.
    Ye, M.
    Huang, J.
    Zhi, X.
    Zhang, Y.
    Xiu, Q.
    Ma, J.
    Zhang, L.
    You, C.
    ANNALS OF ONCOLOGY, 2015, 26 (09) : 1877 - 1883
12345